bioRxivMicrobiologyPreprint
Construction of a potent pan-vaccine based on the evolutionary tendency of SARS-CoV-2 spike protein.
Y. Zhao, W. Ni, S. Liang, L. Dong, M. Xiang, Z. Cai, D. Niu, Q. Zhang, D. Wang, Y. Zheng, Z. Zhang, D. Zhou, W. Guo, Y. Pan, X. Wu, Y. Yang, Z. Jing, Y. Jiang, SARS-CoV-2 Vaccine Task Force Group, Y. Chen, H. Yan, Y. Zhou, K. Xu, K. Lan
Abstract
SARS-CoV-2 continued to spread globally along with different variants. Here, we systemically analyzed viral infectivity and immune-resistance of SARS-CoV-2 variants to explore the underlying rationale of viral mutagenesis. We found that the Beta variant harbors both high infectivity and strong immune resistance, while the Delta variant is the most infectious with only a mild immune-escape ability. Remarkably, the Omicron variant is even more immune-resistant than the Beta variant, but its infectivity increases only in Vero E6 cells implying a probable preference for the endocytic pathway. A comprehensive analysis revealed that SARS-CoV-2 spike protein evolved into distinct evolutionary paths of either high infectivity plus low immune resistance or low infectivity plus high immune resistance, resulting in a narrow spectrum of the current single-strain vaccine. In light of these findings and the phylogenetic analysis of 2674 SARS-CoV-2 S-protein sequences, we generated a consensus antigen (S6) taking the most frequent mutations as a pan-vaccine against heterogeneous variants. As compared to the ancestry SWT vaccine with significantly declined neutralizations to emerging variants, the S6 vaccine elicits broadly neutralizing antibodies and full protections to a wide range of variants. Our work highlights the importance and feasibility of a universal vaccine strategy to fight against antigen drift of SARS-CoV-2.
- organism: virus
- assay: proteomics
- research focus: drug response / drug discovery
- approach: comparative / phylogenetic analysis
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants
M. McCallum, A. C. Walls, … D. Veesler·bioRxiv·Aug 11, 2021
- Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2
L. Liu, S. Iketani, … D. D. Ho·bioRxiv·Dec 14, 2021
- Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
- Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants
A. Banerjee, J. Lew, … D. Falzarano·bioRxiv·Jan 13, 2022
- The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
- Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2
J. M. Otaki, W. Nakasone, M. Nakamura·bioRxiv·Dec 30, 2021